Can hsp90α-targeted siRNA combined with TMZ be a future therapy for glioma

Cancer Investigation

Volumn 28, Issue 6, 2010, Pages 608-614

  Cruickshanks, Nichola ^a   Shervington, Leroy ^a   Patel, Rahima ^a   Munje, Chinmay ^a   Thakkar, Dipti ^a   Shervington, Amal ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

Glioma; Hsp90 ; Normal brain; SiRNA

Indexed keywords

CISPLATIN; DOUBLE STRANDED RNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90 ALPHA; MESSENGER RNA; SMALL INTERFERING RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; HEAT SHOCK PROTEIN 90; HSP90ALPHA PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; ASTROCYTE; ASTROCYTOMA CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; INCUBATION TIME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; BRAIN TUMOR; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; GLIOMA; METABOLISM; METHODOLOGY; PATHOLOGY; RNA INTERFERENCE; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DACARBAZINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GLIOMA; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TIME FACTORS; TRANSFECTION;

EID: 77953224444     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357901003630967     Document Type: Article

References (25)

1. Mosser, D.D.; Morimoto, R.I. Molecular chaperones and the stress of oncogenesis. Oncogene 2004, 23, 2907-2929.
2. Graner, M.; Bigner, D. Chaperone proteins and brain tumours: potential targets and possible therapeutics. Neuro-Oncol 2005, 7, 260-277.
3. Pearl, L.H.; Prodromou, G. Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv Protein Chem 2001, 59, 157-186.
4. Picard, D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol Life Sci 2002, 59, 1640-1648.
5. Pratt, W.B.; Toft, D.O. Regulation of signalling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med 2003, 228, 111-133.
6. Goetz, M.P.; Toft, D.O.; Ames, M.M.; Erlichman, C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003, 14, 1169-1176.
7. Workman, P.; Powers, M. Chaperoning cell death: a critical dual role for Hsp90 in small-cell lung cancer. Nature Chemical Biol 2007, 3, 455-457.
8. Hadden, M.K.; Lubbers, D.J.; Blagg, B.S. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Curr Top Med Chem 2006, 6, 1173-1182.
9. Sreedhar, A.; Kalmár, E.; Csermely, P.; Shen, Y. Hsp90 isoforms: functions, expression and clinical importance. FEBS 2004, 562, 11-15.
10. Pearl, L.H.; Prodromou, G.; Workman, P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008, 410, 439-453.
11. Ciocca, D.R.; Calderwood, S.K. Heat shock proteins in cancer: diagnosis, prognostic predictive and treatment implications. Cell Stress Chaperones 2005, 10, 86-103.
12. Eustace, B.K.; Sakurai, T.; Stewart, T.; Yimlamai, D.; Unger, C.; Zehetmeier, C.; Lain, B.; Torella, C.; Henning, S.W.; Beste, G.; Scroggins, B.T.; Neckers, L.; Ilag, L.; Jay, D.G. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004, 6, 507-514.
13. Chen, X.; Zhang, Y.; Wang, J.; Li, X.; Cheng, X.; Zhang, Y.; Wu, N.; Shen, Y. Diverse effects of Stat1 on the regulation of hsp90 gene under heat shock. J Cell Biochem 2007, 102, 1059-1066.
14. Shervington, A.; Cruickshanks, N.; Lea, R.; Roberts, G.; Dawson, T.; Shervington, L. Can the lack of HSP90α protein in brain normal tissue and cell lines, rationalise it as a possible therapeutic target for gliomas? Cancer Invest 2008, 26, 900-904.
15. Patel, R.; Shervington, L.; Lea, R.; Shervington, A. Epigenetic silencing of telomerase and a non-alkylating agent as a novel therapeutic approach for glioma. Brain Res 2007, 1188, 173-181.
16. Shervington, A.; Lu, C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest 2008, 26, 535-542.
17. Jarvis, R.; King, A. Optimizing chemical transfection and electroporation of siRNAs. Ambion TechNotes 2003, 10, 12-15.
18. Elbashir, S.M.; Martinez, J.; Patkaniowska, A.; Lendeckel, W.; Ttuschl, T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001, 20, 6877-6888.
19. Whitesell, L.; Lindquist, S. Hsp90 and the chaperoning of cancer. Nature Reviews: Cancer 2005, 5, 761-772.
20. Lefranc, F.; Facchini, V.; Kiss, R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a Special Emphasis on Glioblastomas. The Oncologist 2007, 12, 1395-1403.
21. Lum, J.J.; Bauer, D.E.; Kong, M.; Harris, M.H.; Li, C.; Lindsten, T.; Thompson, C.B. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 2005, 120, 237-248.
22. Kanzawa, T.; Germano, I.M.; Komata, T.; Ito, H.; Kondo, Y.; Kondo, S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004, 11, 448-457. (Pubitemid 38489422)
23. Cervantes-Gomez, F.; Nimmanapalli, R.; Gandhi, V. Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and Actinomycin D. Cancer Res 2009, 1, 3947-3954.
24. Workman, P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 2003, 10, 47-51.
25. Khvorova, A.; Reynolds, A.; Jayasena, S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003, 115, 209-216.